Pain & Central Nervous System Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pain & Central Nervous System Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Movement Disorders
Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type a Free From Complexing Proteins)
June 22nd, 2009
Results from three placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented at the Movement Disorder Society (MDS) 13th Annual International Congress in Paris, France. The studies were sponsored by Merz Pharmaceuticals, which plans to file a Biologic License Application (BLA) for NT-201 in the USA in the near future. The NT-201 data presented at the Movement Disorder Society's annual meeting includes the following three abstracts: Efficacy and safety of NT-201 (Xeomin(R); botulinum neurotoxin type A free from complexing...
Source: Pain & Central Nervous System Week (2009-06-22)
|
